Brokers Issue Forecasts for Kura Oncology FY2026 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Equities research analysts at Leerink Partnrs issued their FY2026 earnings per share estimates for Kura Oncology in a research note issued on Wednesday, February 26th. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings of ($1.05) per share for the year. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

A number of other research firms have also recently weighed in on KURA. BTIG Research cut shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. TD Cowen restated a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. JMP Securities reissued a “market outperform” rating and set a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th. Bank of America dropped their target price on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, November 22nd. Finally, Scotiabank reduced their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Kura Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $27.13.

Kura Oncology Trading Down 6.0 %

NASDAQ KURA opened at $7.25 on Monday. The company’s fifty day simple moving average is $8.14 and its 200-day simple moving average is $13.73. The stock has a market cap of $563.79 million, a P/E ratio of -3.07 and a beta of 0.78. Kura Oncology has a 52 week low of $6.98 and a 52 week high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.43. The company had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million.

Institutional Trading of Kura Oncology

A number of hedge funds have recently bought and sold shares of KURA. Virtus ETF Advisers LLC increased its position in shares of Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after acquiring an additional 3,061 shares in the last quarter. Harbor Advisors LLC acquired a new position in Kura Oncology in the 4th quarter worth approximately $87,000. E Fund Management Co. Ltd. purchased a new position in Kura Oncology during the 4th quarter worth approximately $90,000. Corton Capital Inc. acquired a new stake in Kura Oncology during the 4th quarter valued at $99,000. Finally, Optimize Financial Inc purchased a new stake in shares of Kura Oncology in the fourth quarter valued at $100,000.

Insiders Place Their Bets

In other news, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock valued at $92,307 over the last quarter. Insiders own 5.50% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.